Concepedia

Publication | Closed Access

The nontoxic tripeptide glycyl-prolyl-glycine amide inhibits the replication of human immunodeficiency virus type 1.

19

Citations

0

References

2001

Year

Jianguo Su, Emmi Andersson, Peter Horal, Mojgan H. Naghavi, Anna-Karin E. Palm, Yingchun Wu, Kimmo Eriksson, Marianne Jansson, Hans Wigzell, Bo Svennerholm,
PubMed

Abstract

The tripeptide GPG-NH2 is a nontoxic compound that inhibits the replication of HIV-1 by an apparently new mode of action. Glycyl-prolyl-glycine-NH2 might prove useful by itself or as a lead compound for the treatment of drug-resistant HIV-1. Glycyl-prolyl-glycine-NH2 is currently undergoing phase I/II human clinical trials in Sweden.